Shares in US biotech Arrowhead Pharmaceuticals took a tumble after the FDA put a clinical hold on one of its small interfering RNAs (siRNAs) Phase II programs in hepatitis B because of concerns over a delivery vehicle that is also used in two of its other Phase II candidates.
Arrowhead Pharmaceuticals Inc.’ share priced dropped by more than 26% to $4.5 on early trading on NASDAQ on Nov. 11 following news that the US FDA has placed on clinical hold Heparc-2004, a Phase IIb study of ARC-520, its investigational therapeutic vaccine for the treatment of chronic hepatitis B virus (HBV) infection.
Though still to be confirmed in writing, the company said it had been told verbally by the agency that the...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
